SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-13-000263
Filing Date
2013-02-14
Accepted
2013-02-14 16:37:03
Documents
11
Period of Report
2012-12-31

Document Format Files

Seq Description Document Type Size
1 vsta10qdec312012.htm 10-Q 1183414
2 NPEA AMENDMENT NO 2 TO NOTE EXCHANGE AND PURCHASE AGREEMENT npeaamend.htm EX-10.1 32537
3 ex31-1.htm EX-31.1 8997
4 ex31-2.htm EX-31.2 9078
5 ex32.htm EX-32 5808
  Complete submission text file 0001415889-13-000263.txt   5833608

Data Files

Seq Description Document Type Size
6 vsta-20121231.xml EX-101.INS 850953
7 vsta-20121231.xsd EX-101.SCH 86532
8 vsta-20121231_pre.xml EX-101.PRE 230830
9 vsta-20121231_lab.xml EX-101.LAB 413659
10 vsta-20121231_def.xml EX-101.DEF 120767
11 vsta-20121231_cal.xml EX-101.CAL 55750
Mailing Address 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Business Address 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 650-244-9997 X224
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54014 | Film No.: 13614803
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences